No Data
No Data
Trad Chi Med (00570.HK) held a board of directors meeting on August 28 to consider and approve its mid-year performance.
China trad chi med (00570.HK) announced on August 16th that the board of directors will hold a meeting on August 28th, 2024 (Wednesday) to consider and approve the mid-term performance of the company and its subsidiaries for the six months ended on June 30, 2024, including its release.
Hong Kong stocks surged | Traditional Chinese medicine (00570) rose more than 8%, and the company disclosed the latest situation of privatization.
Trad chi med (00570) rose more than 8%. As of press time, it rose by 8.44% to HKD 4.11, with a turnover of HKD 0.31 billion.
HK stocks anomaly | China Traditional Chinese Medicine (00570) rose again nearly 5%, up more than 15% within the month. The market continues to pay attention to the company's privatization process.
Trad chi med (00570) rose nearly 5%, with a cumulative increase of over 15% this month. As of the time of publication, it has risen 4.97%, to HKD 3.8, with a turnover of HKD 0.143 billion.
Hong Kong stock market fluctuation | Chinese traditional medicine (00570) continued to fall by more than 5%, with a drop of nearly 12% yesterday. The privatization process has attracted market attention.
According to the Zhītōng Cáijīng app, trad chi med (00570) continued to fall by more than 5% and closed down nearly 12% yesterday. As of press time, it was down 4.88% at HKD 3.51 with a turnover of HKD 167 million. In February of this year, trad chi med announced that C.N. Pharmaceutical Group was planning to privatize trad chi med for HKD 4.6 per share, approximately 34.11% higher than the closing price of HKD 3.43 per share before the trading suspension. Based on C.N. Pharmaceutical Group's shareholding ratio, the total cost of this privatization is about HKD 15.45 billion. Trad chi med believes that the reason for this privatization is due to...
China Traditional Chinese Medicine (00570) fell more than 10% with its granule sales forecasts being downgraded. At the beginning of the year, it received a premium privatization offer from China National Pharmaceutical Group Co., Ltd.
Trad Chi Med (00570) fell more than 10%, as of press time, fell 10.05%, reported HKD 3.77, with a turnover of HKD 212 million.
Huafu Securities: The wave of state-owned enterprise reforms continues to deepen and the potential for state-owned pharmaceutical companies as symbols is enormous.
In the context of deepening state-owned enterprise reform and the new 'Nine Rules for the State', top central enterprises are expected to realize the catalysis of bullish resource integration, operational improvement, personnel optimization, and increased dividends.
No Data